EP Patent

EP0325843A2 — Pharmaceutical formulations for preventing drug tolerance

Assigned to Elan Corp PLC · Expires 1989-08-02 · 37y expired

What this patent protects

Pharmaceutical formulations for once-daily administration of a drug to inhibit the development of drug tolerance in humans being treated with the drug which can achieve therapeutically effective levels of said drug in the plasma over a period of not more than 20 hours of the day …

USPTO Abstract

Pharmaceutical formulations for once-daily administration of a drug to inhibit the development of drug tolerance in humans being treated with the drug which can achieve therapeutically effective levels of said drug in the plasma over a period of not more than 20 hours of the day and then cause said blood levels to fall significantiy below the therapeutic levels throughout the remainder of the 24 hour period. The formulations are adapted for either oral or percutaneous administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP0325843A2
Jurisdiction
EP
Classification
—
Expires
1989-08-02
Drug substance claim
No
Drug product claim
No
Assignee
Elan Corp PLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.